Catalyst Pharmaceutical CPRX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's additional paid-in capital?
- Catalyst Pharmaceutical (CPRX) reported additional paid-in capital of $489.22M in Q1 2026.
- How has Catalyst Pharmaceutical's additional paid-in capital changed year-over-year?
- Catalyst Pharmaceutical's additional paid-in capital increased by 8.2% year-over-year, from $452.28M to $489.22M.
- What is the long-term trend for Catalyst Pharmaceutical's additional paid-in capital?
- Over 5 years (2020 to 2025), Catalyst Pharmaceutical's additional paid-in capital has grown at a 16.6% compound annual growth rate (CAGR), from $223.17M to $479.96M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.